A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

NCT01013753 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Placebo
DRUG: Olodaterol (BI 1744) high
DRUG: Olodaterol (BI 1744) medium
DRUG: Olodaterol (BI 1744) very low
DRUG: Formoterol 12 mcg
DRUG: Olodaterol (BI 1744) low

Sponsor

Boehringer Ingelheim